Drugmaker Hikma Pharmaceuticals turned in a solid first half on Thursday, with group revenues rising 4% to $1.73bn, driven by a strong performance in its branded unit and stable contributions from both injectables and Hikma Rx.
Hikma Pharmaceuticals
06 August 2026 09:50:10
Source: Sharecast
Hikma said branded revenue jumped 15% to $502m, while injectables and Hikma Rx were broadly flat year-on-year at $685m and $520m, respectively.
As a result, core operating profits increased 9% to $405m, giving a margin of 23.4%. Branded was the standout performer, with core operating profit up 23% and margins rising to 32.5%. Hikma Rx posted 16% growth with a 20.6% margin, while injectables saw an 8% decline in core operating profit and a margin of 27.6%. Reported operating profits rose 30% to $336m, reflecting a lower comparator after last year's non‑core legal settlement.
Cashflow from operating activities strengthened to $214m, up from $161m, while net debt increased to 1.9x core EBITDA following investment and the firm's ongoing $250m share buyback - of which it has now purchased $227m.
The FTSE 250-listed firm also lifted its interim dividend by 6% to $0.38 per share.
Looking ahead, Hikma reiterated its full‑year guidance for 2% to 4% constant‑currency revenue growth and core operating profits of $720m to $770m, supported by momentum in branded and improving margins across its portfolio.
As of 0950 BST, Hikma shares were up 9.36% at 1,718p.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
